Clinical Trials

The purpose of this study is to analyze and report orbital decompression outcomes in patients with a thyroid eye disease diagnosis.

The objective is to show that balanced orbital decompression will reduce preoperative Hertel’s measurement when compared to measurements done intraoperatively and remain stable at three-month follow-up. Additionally, to see increased patient satisfaction and quality of life regarding cosmesis when comparing pre and postoperative satisfaction surveys.

The purpose of this study is to evaluate the safety, effectiveness and need for re-treatment of 3 different teprotumumab treatment durations for thyroid eye disease (TED). In addition, serum samples from patients with a Baseline Clinical Activity Score (CAS) ≥ 3 will be evaluated for biomarkers of disease.

Teprotumumab was approved by the United States Food and Drug Administration on 21 January 2020 for the treatment of TED under the name TEPEZZA® (teprotumumab-trbw). 

This is a clinical trial assessing the safety and tolerability of an investigational drug, VRDN-003, in participants with Thyroid Eye Disease (TED).

The primary purpose of this study is to investigate the effectiveness, safety and tolerability of TEPEZZA® (teprotumumab-trbw) in comparison to placebo in treating patients with chronic (inactive) TED.

We plan to create a databank of serum and tissue samples from patients with thyroid autoimmunity, mainly focusing on Graves’ disease and Graves’ orbitopathy, respectively. This set of samples will allow us to study these disorders better in the laboratory as well as test potential agents that can be used as therapies.

The purpose of this study is to perform a comprehensive immunophenotypic analysis of peripheral bloods samples from patients with benign and malignant thyroid disease. This data will be used to determine whether patients with advanced thyroid cancers have significantly altered numbers and/or subtypes of circulating immune cells, in particular immunosuppressive monocytes.